

CF Reference List

(collected 20th May – 19th September)

Adults & Adolescents

Cohen-Cymberknoh M., Garber KM., Reiter J., Shteinberg M, Stolovas A., Barghouti I, Adler Lazarovits C., Esh Broder E., Hershko Klement A.

Ovarian reserve in women with cystic fibrosis: is this a cause of sub-fertility?

Journal of Ovarian Research 2023; 16: 148

Godfrey EM., Schwartz MR., Stukovsky KDH., Woodward D., Magaret AS., Aitken ML.

Web-Based Survey Piloting Process as a Model for Developing and Testing Past Contraceptive Use and Pregnancy History: Cystic Fibrosis Case Study.

JMIR Formative Research. 2023; 7: :e46395

Rhoads S., Auth R., Chambers A., Blundin M., Mahoney L., McLaughlin S., Banerjee D.

Perceptions and Use of E-cigarettes among Young Adults with Cystic Fibrosis: An Observational Study.

Rhode Island Medical Journal 2023; 106: 58-63.

Animal Model

Verstraete L., Aizawa J., Govaerts M., De Vooght L., Lavigne R., Michiels J., Van den Bergh B., Cos P.

In Vitro Persistence Level Reflects In Vivo Antibiotic Survival of Natural *Pseudomonas aeruginosa* Isolates in a Murine Lung Infection Model.

Microbiology Spectrum 2023; 11: e0497022

Antimicrobials

Al-Momani H., Almasri M., Al Balawi D., Hamed S., Albiss BA., Aldabaibeh N., Ibrahim L., Albalawi H., Al Haj Mahmoud S., Khasawneh AI., Kilani M., Aldhafeeri M., Bani-Hani M., Wilcox M., Pearson J., Ward C.

The efficacy of biosynthesized silver nanoparticles against *Pseudomonas aeruginosa* isolates from cystic fibrosis patients.

Scientific Reports 2023; 13: e8876

Di Bonaventura G, Lupetti V, Di Giulio A, Muzzi M, Piccirilli A, Cariani L, Pompilio A.

Repurposing High-Throughput Screening Identifies Unconventional Drugs with Antibacterial and Antibiofilm Activities against *Pseudomonas aeruginosa* under Experimental Conditions Relevant to Cystic Fibrosis.

Microbiology Spectrum. 2023; 11: :e0035223

Chen J., Thrasher K., Fu L., Wang W., Aghamohammadzadeh S., Wen H., Tang L., Keeling KM., Falk Libby E., Bedwell DM., Rowe SM.

The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators.

American Journal of Physiology-Lung Cellular and Molecular Physiology. 2023; 324: L756-L770

Cogen JD., Sanders DB., Slaven JE., Faino AV., Somayaji R., Gibson RL., Hoffman LR., Ren CL.

Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.

Annals of the. American Thoracic Society 2023; 20: 1293-1298

de la Rosa-Carrillo D, Suárez-Cuartín G, Sibila O, Golpe R, Girón RM, Martínez-García MÁ.

Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review.

Journal of Clinical Medicine 2023; 12: e3577

Hills OJ., Poskrobko Z., Scott AJ., Smith J., Chappell HF..

A DFT study of the gallium ion-binding capacity of mature *Pseudomonas aeruginosa* biofilm extracellular polysaccharide.

PLoS One 2023; 18: e0287191

Holzinger JM., Toelge M., Werner M., Ederer KU., Siegmund HI., Peterhoff D., Blaas SH., Gisch N., Brochhausen C., Gessner A., Bülow S.

Scorpionfish BPI is highly active against multiple drug-resistant *Pseudomonas aeruginosa* isolates from people with cystic fibrosis.

eLife 2023; 12: e86369

Katz JB., Shah P., Trillo CA., Alshaer MH., Peloquin C., Lascano J.

Therapeutic drug monitoring in cystic fibrosis and associations with pulmonary exacerbations and lung function.

Respiratory Medicine 2023; 212: e107237

Kostoulas X., Chang CC., Wisniewski J., Abbott IJ., Zisis H., Dennison A., Spelman DW., Peleg AY.

Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant *Pseudomonas aeruginosa* isolates from Melbourne, Australia.

Pathology 2023; 55: 663-668

Langton Hewer SC., Smith S., Rowbotham NJ., Yule A., Smyth AR.

Antibiotic strategies for eradicating *Pseudomonas aeruginosa* in people with cystic fibrosis.
Cochrane Database of Systematic Reviews 2023; 6: CD004197

Maset RG., Hapeshi A., Lapage J., Harrington N., Littler J., Perrier S., Harrison F.

Combining SNAPs with antibiotics shows enhanced synergistic efficacy against *S. aureus* and *P. aeruginosa* biofilms.
NPJ Biofilms Microbiomes. 2023; 9: e36

Monogue ML., Sanders JM., Pybus CA., Kim J., Zhan X., Clark AE., Greenberg DE.

Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related *Pseudomonas aeruginosa* infections.
JAC-Antimicrobial Resistance. 2023; 5: dlad083.

Naehrig S., Schulte-Hubbert B., Hafkemeyer S., Hammermann J., Dumke M., Sieber S.; Registry working group of the German CF Registry;

Chronic inhaled antibiotic therapy in people with cystic fibrosis with *Pseudomonas aeruginosa* infection in Germany.
Pulmonary Pharmacology and Therapeutics . 2023; 80: e102214

Olbrecht M., Echahidi F., Piérard D., Peeters C., Vandamme P., Wybo I., Demuyser T.

In Vitro Susceptibility of *Achromobacter* Species Isolated from Cystic Fibrosis Patients: a 6-Year Survey.
Antimicrobial Agents and Chemotherapy. 2023; e0037923

Rademacher J., Martin L., Theloe A., Stahl M., Mall MA., Joean O., Fuge J(1)., Hansen G., Welte T., Schütz K., Ringshausen FC., Dittrich AM. Optimal treatment of the underlying aetiology is the most effective antimicrobial stewardship for chronic respiratory disease: a lesson learned from cystic fibrosis.

ERJ Open Research 2023; 9: 00356

Saha S., Ojabor CD., Li ASC., Mackinnon E., North OI., Bondy-Denomy J., Lam JS., Ensminger AW., Maxwell KL., Davidson AR.

F-Type Pyocins Are Diverse Noncontractile Phage Tail-Like Weapons for Killing *Pseudomonas aeruginosa*.
Journal of Bacteriology 2023; 205: e0002923.

Tait JR, Harper M, Cortés-Lara S, Rogers KE, López-Causapé C, Smallman TR, Lang Y, Lee WL, Zhou J, Bulitta JB, Nation RL, Boyce JD, Oliver A, Landersdorfer CB.

Ceftolozane-Tazobactam against *Pseudomonas aeruginosa* Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.
Antimicrobial Agents and Chemotherapy 2023; 67: e0041423

Uzi-Gavrilov S., Tik Z., Sabti O., Meijler MM. Chemical Modification of a Bacterial Siderophore by a Competitor in Dual-Species Biofilms

Angewandte Chemie International Edition 2023; 62: e202300585.

Zheng X, Gao M, Wu L, Lu X, Lin Q, Zhong H, Lu Y, Zhang Y, Zhang X

Ceftazidime-assisted synthesis of ultrasmall chitosan nanoparticles for biofilm penetration and eradication of *Pseudomonas aeruginosa*.
Scientific Reports 2023; 13: e13481

CFTR

Amistadi S., Maule G., Ciciani M., Ensink MM., De Keersmaecker L., Ramalho AS., Guidone D., Buccirosi M., Galletta LJV., Carlon MS., Cereseto A.

Functional restoration of a CFTR splicing mutation through RNA delivery of CRISPR adenine base editor.
Molecular Therapy 2023; 31: 1647-1660

Aridgides DS., Mellinger DL., Gwilt LL., Hampton TH., Mould DL., Hogan DA., Ashare A.

Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages.
Scientific Reports 2023; 13: e11995

Csanády L.

Blue flash sheds light on the roles of individual phosphoserines in CFTR channel activation.
Journal of General Physiology 2023; 155: e202313336

Deignan JL., Gregg AR., Grody WW., Guo MH., Kearney H., Monaghan KG., Raraigh KS., Taylor J., Zepeda-Mendoza CJ., Ziats C.; et al

Updated recommendations for CFTR carrier screening: A position statement of the American College of Medical Genetics and Genomics (ACMG)
Genetics in Medicine 2023; 25: e100867

Dobi D., Loberto N., Bassi R., Pistocchi A., Lunghi G., Tamanini A., Aureli M.

Cross-talk between CFTR and sphingolipids in cystic fibrosis.

FEBS Open Bio. 2023; 13: 1601-1614

Earnhardt EY., Tipper JL., D'Mello A., Jian MY., Conway ES., Mobley JA., Orihuela CJ., Tettelin H., Harrod KS.

Influenza A-induced cystic fibrosis transmembrane conductance regulator dysfunction increases susceptibility to *Streptococcus pneumoniae*.

JCI Insight 2023; 8: e170022

Gifford AH., Mayer-Hamblett N., Nichols DP..

Reducing treatment burden in the era of CFTR modulators - Authors' reply.

Lancet Respiratory Medicine 2023; 11: e79.

Joynt AT., Kavanagh EW., Newby GA., Mitchell S., Eastman AC., Paul KC., Bowling AD., Osorio DL., Merlo CA., Patel SU., Raraigh KS., Liu DR., Sharma N., Cutting GR.

Protospacer modification improves base editing of a canonical splice site variant and recovery of CFTR function in human airway epithelial cells.

Molecular Therapy Nucleic Acids 2023; 33: 335-350.

Kramer EL., Hudock KM., Davidson CR., Clancy JP.

CFTR dysfunction in smooth muscle drives TGF β dependent airway hyperreactivity.

Respiratory Research 2023; 24: e198

Lester A, Sandman M., Herring C., Girard C., Dixon B., Ramsdell H., Reber C., Poulos J., Mitchell A., Spinney A., Henager ME., Evans CN., Turlington M., Johnson QR.

Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs.

Biochemistry 2023; 62: :2503-2515.

Robinson PD., Douglas TA., Wainwright CE.

Reducing treatment burden in the era of CFTR modulators.

Lancet Respiratory Medicine 2023; 11: e78

Sato Y., Kim D., Turner MJ., Luo Y., Zaidi SSZ., Thomas DY., Hanrahan JW.

Ionocyte-Specific Regulation of Cystic Fibrosis Transmembrane Conductance Regulator.

American Journal of Respiratory Cell and Molecular Biology 2023; 69: 281-294

Stefania LC., Germana C., Giovanna B., Maria BS., Giovanni S., Riccardo P., Rachela VV., Speranza E., Immacolata Z., Francesca S., Ruggero M. Mauro B., Giuseppe C., Felice A., Marco L., Adriana E.

L1077P CFTR pathogenic variant function rescue by Elexacaftor-Tezacaftor-Ivacaftor in cystic fibrosis patient-derived air-liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients.

Respiratory Research ; 24: :217

Taniguchi S., Fukuda R., Okiyonedo T.

The multiple ubiquitination mechanisms in CFTR peripheral quality control.

Biochemical Society Transactions 2023; 51: 1297-1306

Taniguchi S., Ono Y., Doi Y., Taniguchi S., Matsuura Y., Iwasaki A., Hirata N., Fukuda R., Inoue K., Yamaguchi M., Tashiro A., Egami D., Aoki S., Kondoh Y., Honda K., Osada H., Kumeta H., Saio T., Okiyonedo T.

Identification of α -Tocopherol succinate as an RFFL-substrate interaction inhibitor inducing peripheral CFTR stabilization and apoptosis.

Biochemical Pharmacology. 2023; 215: 115730

Woodall M., Tarran R., Lee R., Anfishi H., Prins S., Counsell J., Vergani P., Hart S., Baines D.

Expression of gain-of-function CFTR in cystic fibrosis airway cells restores epithelial function better than wild-type or codon-optimized CFTR.

Methods & Clinical Development 2023; 30: 593-605

Cardiology

Gürel E., Vezir D., Güçtekin T., Doğan Z., Kocakaya D., Olgun S., Sünbül M., Çiğin A., Özben B., Sayar N., Tigen MK., Ceyhan B.

The Impact of Cystic Fibrosis- and Noncystic Fibrosis-Bronchiectasis on Pulmonary Artery Wall Thickness and Right Heart Functions Assessed by Speckle-Tracking Echocardiography.

Anatolian Journal of Cardiology 2023; 27: 319-327

Jayaraman J.

Adolescent Patient with Cystic Fibrosis Presents with Suspected Ludwig Angina.

Dental Clinics of North America 2023; 67: 443-446

Cell Biology

Castaneda DC, Jangra S, Yurieva M, Martinek J, Callender M, Coxe M, Choi A, García-Bernalt Diego J, Lin J, Wu TC, Marches F, Chaussabel D, Yu P, Salner A, Aucello G, Koff J, Hudson B, Church SE, Gorman K, Anguiano E, García-Sastre A, Williams A, et al

Spatiotemporally organized immunomodulatory response to SARS-CoV-2 virus in primary human broncho-alveolar epithelia
iScience 2023; 26: e107374

Kerschner JL, Paranjapye A, Harris A.

Cellular heterogeneity in the 16HBE14o(-) airway epithelial line impacts biological readouts.

Physiological Reports 2023; 11: :e15700

Kim SO., Shapiro JP., Cottrill KA., Collins GL., Shanthikumar S., Rao P., Ranganathan S., Stick SM., Orr ML., Fitzpatrick AM., Go YM., Jones DP., Tirouvanziam RM., Chandler JD.

Substrate-dependent metabolomic signatures of myeloperoxidase activity in airway epithelial cells: Implications for early cystic fibrosis lung disease. *Free Radical Biology and Medicine* 2023; 206: 180-190

Kothiya AB., Adlakha N.

Cellular nitric oxide synthesis is affected by disorders in the interdependent and dynamics during cystic fibrosis disease.

Journal of Biological Physics 2023; 49: 133-158

Mikami Y., Grubb BR., Rogers TD., Dang H., Asakura T., Kota P., Gilmore RC., Okuda K., Morton LC., Sun L., Chen G., Wykoff JA., Ehre C., Vilar J., van Heusden C., Livraghi-Butrico A., Gentzsch M., Button B., Stutts MJ., Randell SH., O'Neal WK., et al.

Chronic airway epithelial hypoxia exacerbates injury in muco-obstructive lung disease through mucus hyperconcentration.

Science Translational Medicine. 2023; 15: eabo7728

Clinical

Allouzi S, Rihawi B., Allouzi J., Allouzi MI., Abdulrahman N., Abdullah M.

A unique presentation of hyponatremia and seizures in a 2-month-old child with cystic fibrosis: a case report.

Annals of Medicine and Surgery 2023; 85: 4150-4152.

Bagatini MA., Heinzmann-Filho JP., Vendrusculo FM., Pinto LA., Donadio MVF.

Impact of COVID-19 social distancing recommendations on pulmonary function, nutritional status, and morbidity in patients with cystic fibrosis.

Revista Paulista de Pediatria 2023; 42: e2022198

Dell'Anno I., Calabria S., Dondi L., Ronconi G., Dondi L., Addesi A., Pedrini A., Esposito I., Maggioni AP., Martini N., Piccinni C.

PDTA Net come strumento per l'analisi dei percorsi regionali delle malattie rare: l'esempio della fibrosi cistica.

Recenti progressi in medicina 2023; 114: 534-535

Edmondson C., Lechtzin N.

Telemedicine and remote monitoring in cystic fibrosis.

Current Opinion in Pulmonary Medicine 2023; 29: 277-284.

Goralski JL., Hoppe JE., Mall MA., McColley SA., McKone E., Ramsey B., Rayment JH., Robinson P., Stehling F., Taylor-Cousar JL., Tullis E., Ahluwalia N., Chin A(16), Chu C., Lu M., Niu T., Weinstock T., Ratjen F., Rosenfeld M..

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele

American Journal of Respiratory and Critical Care Medicine 2023; 208: 59-67.

Ifikhar J., Hendrix-Dicken AD., Kezbers KM., Stuemky L., Bell SB., Condren M.

Cystic fibrosis fitness during inpatient treatment (CF-FIT): A pre-post pilot study.

Pediatric Pulmonology. 2023; 58: :2675-2677.

Richards CJ., Friedman D., Pinsky H.,

Gootkind E., Lee H., Yonker L.,

Georgiopoulos AM

Alcohol and opiate misuse in adults with cystic fibrosis.

Pediatric Pulmonology 2023; 58: 2535-2542

Ward A., Mauleon R., Arellano J., Ooi CY., Rosic N.

Critical disease burdens of Australian adults with cystic fibrosis: Results from an online survey.

Pediatric Pulmonology 2023; 58: :1931-1941

Diabetes

Ekblond RS., Nielsen BU., Højte C., Almdal TP., Shaw J., Pressler T., Faurholt-Jepsen D., Mathiesen IHM.
Changes in glucose tolerance in people with cystic fibrosis after initiation of first-generation CFTR modulator treatment. *Pediatric Pulmonology*. 2023; 58: 2600-2609

Finn E., Severn C., Pyle L., Garrish J., Vigers T., Behn CGD., Zeitler PS., Sagel SD., Nadeau KJ., Chan CL.
Hypoglycemia in children and young adults with cystic fibrosis during oral glucose tolerance testing vs. continuous glucose monitoring. *Pediatric Pulmonology* 2023; 58: 2495-2504

Lurquin F., Gohy S., Hermans MP., Preumont V.
Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes. *Journal of Clinical and Translational Endocrinology* 2023; 33: 100320.

Putman MS., Norris AW., Hull RL., Rickels MR., Sussel L., Blackman SM., Chan CL., Ode KL., Daley T., Stecenko AA., Moran A., Helmick MJ., Cray S., Alvarez JA., Stallings VA., Tuggle KL., Clancy JP., Eggerman TL., Engelhardt JF., Kelly A.
Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes. *Diabetes* 2023; 72: 677-689

Schiaffini R., Pampanini V.
Diabetes and prediabetes in children with cystic fibrosis. *Current Opinion in Pediatrics* 2023; 35: 481-485.

Suppakitjanusant P., Kasemkosin N., Sivapiromrat AK., Weinstein S., Ongphiphadhanakul B., Hunt WR., Sueblinvong V., Tangpricha V.
Author Correction: Predicting glycemic control status and high blood glucose levels through voice characteristic analysis in patients with cystic fibrosis-related diabetes (CFRD). *Scientific Reports*. 2023; 13: e10707.

Suppakitjanusant P., Kasemkosin N., Sivapiromrat AK., Weinstein S., Ongphiphadhanakul B., Hunt WR., Sueblinvong V., Tangpricha V.
Predicting glycemic control status and high blood glucose levels through voice characteristic analysis in patients with cystic fibrosis-related diabetes (CFRD). *Scientific Reports*. 2023; 13: e8617

Epidemiology

Abubakar Bobbo K., Ahmad U., Chau DM., Nordin N., Abdullah S.
A comprehensive review of cystic fibrosis in Africa and Asia. *Saudi Journal of Biological Sciences* 2023; 30: e103685

Singh H., Jani C., Marshall DC., Franco R., Bhatt P., Podder S., Shalhoub J., Kurman JS., Nanchal R., Uluer AZ., Salciccioli JD.
Cystic fibrosis-related mortality in the United States from 1999 to 2020: an observational analysis of time trends and disparities. *Scientific Reports* 2023; 13: e15030

Exercise

Corde J., E Holland A., Berry CD., Westrupp N., Cox NS.
Validation of the 25 level modified shuttle test in children with cystic fibrosis. *Pediatric Pulmonology*. 2023; 58: 2240-2248

Gambazza S., Carta F., Ambrogi F., Bassotti G., Brivio A., Russo M., Colombo C
Limitations of the dichotomized 6-minute walk distance when computing lung allocation score for cystic fibrosis: a 16-year retrospective cohort study. *Journal of disability & rehabilitation*. 2023; 45: 2578-2584

Pinto ACPN., Piva SR., Rocha A., Gomes-Neto M., Atallah ÁN., Saconato H., Trevisani VF.
Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis. *Cochrane Database of Systematic Reviews* 2023; 9: CD014605

Gastroenterology

Bu X., Sun P., Wan Y.
Meconium thorax observed in a Chinese neonate with cystic fibrosis. *Pediatric Pulmonology*. 2023; 58: :2151-2153

Duong JT., Sellers ZM.
Cystic Fibrosis-Associated Gastrointestinal Disease in Neonates. *NeoReviews* 2023; 24: e414-e430

General Review

Ong T., Ramsey BW.
Cystic Fibrosis: A Review. *JAMA*. 2023; 329: 1859-1871

Ramsey B., Bush A.

Cystic Fibrosis: From Tragedy to Triumph.
American Journal of Respiratory and Critical Care Medicine. 2023; 208: 9-11

Rowbotham NJ., Smith S., Elliott ZC., Cupid B., Allen LJ., Cowan K., Allen L., Smyth AR.

A refresh of the top 10 research priorities in cystic fibrosis.
Thorax 2023; 78: 840-843.

Genetics

Kalra S., Cho MH.

Who Modifies the Modifiers: A High-Resolution View of the Genetic Modifiers of Cystic Fibrosis.
American Journal of Respiratory and Critical Care Medicine. 2023; 207: 1261-1262

Santos LG., Pereira SV., Kmit AHP., Bonadia LC., Bertuzzo CS., Ribeiro JD., Mazzola TN., Marson FAL.

Identification of single nucleotide variants in SLC26A9 gene in patients with cystic fibrosis (p.Phe508del homozygous) and its association to Orkambi® (Lumacaftor and Ivacaftor) response in vitro.

Gene 2023; 30: e;871:

Soares CA., Tkachenko N., Vale-Fernandes E., Barreiro M., Abreu M., Reis CF., Soares G., Fortuna AM., Soares AR.

Genetic counseling and carrier screening in candidates for gamete donation at a Portuguese center.

JBRA Assisted Reproduction 2023; 27: 180-184

Zheng Z, Song Y, Tan X.

Deciphering HERG mutation in long QT syndrome type 2 using antisense oligonucleotide-mediated techniques: Lessons from cystic fibrosis.

Heart Rhythm 2023; 20: 1169-1177

Zhou YH., Gallins PJ., Pace RG., Dang H., Aksit MA., Blue EE., Buckingham KJ., Collaco JM., Faino AV., Gordon WW, Hetrick KN, Ling H, Liu W, Onchiri FM, Pagel K, Pugh EW, Raraigh KS., Rosenfeld M., Sun Q., Wen J., Li Y., Corvol H., Strug LJ., et al

Genetic Modifiers of Cystic Fibrosis Lung Disease Severity: Whole-Genome Analysis of 7,840 Patients.

American Journal of Respiratory and Critical Care Medicine 2023; 207: 1324-1333

Growth & Development

Bagci R., Vardar-Yagli N., Saglam M., Calik Kutukcu E., Inal-Ince D., Sener F., Damadoglu E.

Body functions and structure, activity, and participation limitations of adult cystic fibrosis patients under the international classification of functioning, disability, and health framework.

Physiotherapy Theory and Practice 2023; 39: 1417-1427

Nayir Buyuksahin H., Dogru D., Gözmen O., Ozon A., Portakal O., Emiralioglu N., Haliloglu M., Kilic K., Vardar Yagli N., Yildirim D., Dag O., Guzelkas I., Yalcin E., Ozelik U., Kiper N..

Cystic fibrosis related bone disease in children: Can it be predicted?

Clinical Nutrition 2023; 42: 1631-1636

Immunology & Inflammation

Alicandro G., Orena BS., Rosazza C., Cariani L., Russo M., Zatelli M., Badolato R., Gramegna A., Blasi F., Daccò V.

Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis.

Vaccine 2023; 41: 4114-4120

Bojanowski CM., Bitoun JP., Kolls JK.

An ALARMING Type 2 Response in Cystic Fibrosis-The Key to Understanding ABPA?
American Journal of Respiratory and Critical Care Medicine 2023; 207: 1418-1419

Cook DP., Thomas CM., Wu AY., Rusznak M., Zhang J., Zhou W., Cephus JY., Gibson-Corley KN., Polosukhin VV., Norlander AE., Newcomb DC., Stoltz DA., Peebles RS Jr.

Cystic Fibrosis Reprograms Airway Epithelial IL-33 Release and Licenses IL-33-Dependent Inflammation.

American Journal of Respiratory and Critical Care Medicine 2023; 207: 1486-1497

Gillan JL., Chokshi M., Hardisty GR., Clohisey Hendry S., Prasca-Chamorro D., Robinson NJ., Lasota B., Clark R, Murphy L., Whyte MKB., Baillie JK., Davidson DJ., Bao G., Gray RD.

CAGE sequencing reveals CFTR-dependent dysregulation of type I IFN signaling in activated cystic fibrosis macrophages.

Science Advances 2023; 9: eadg5128

Jennings S., Hu Y., Wellems D., Luo M., Scull C., Taylor CM., Nauseef WM., Wang G.
Neutrophil defect and lung pathogen selection in cystic fibrosis.
Journal of Leukocyte Biology 2023; 113: 604-614

Liver Disease

Bignamini E., Pinon M.
Effects of CFTR modulator therapies on liver stiffness and bile flow: A single-centre experience.

Journal of Hepatology 2023; 79: :e76-e78

Calvo PL., Giugliano L., Evangelista A., Dana J., Debray D., Vilgrain V.

Reply to: "The effects of CFTR modulator therapies on liver stiffness and bile flow: A single-centre experience".

Journal of Hepatology 2023; 79: e78-e80.

Costaguta G., Patey N., Álvarez F

Cystic fibrosis liver disease in children - A review of our current understanding

Archivos argentinos de pediatria. 2023; 121: :e202202905

ONeill JP., Clifford CS., Nolan NP., McCormick PA.

Non-cirrhotic portal hypertension (obliterative portal venopathy) is the predominant form of chronic liver disease in cystic fibrosis.

Irish Journal of Medical Science. 2023; 192: 1657-1660.

Sakhuja S., Staples HM., Minard CG., Ramm LE., Lewindon PJ., Ramm GA., Leung DH.

Risk factors for more rapid progression of severe liver fibrosis in children with cystic fibrosis-related liver disease: A multi-center study validated by liver biopsy.

Liver International 2023; 43: 1277-1286.

Microbiology

Akkerman-Nijland AM., Rottier BL., Holstein J., Winter RLJ., Touw DJ., Akkerman OW., Koppelman GH.

Eradication of Burkholderia cepacia complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole.

ERJ Open Research 2023; 9: 00055-2023.

Bradley JS., Hajama H., Akong K., Jordan M., Stout D., Rowe RS., Conrad DJ., Hingtgen S., Segall AM.

Bacteriophage Therapy of Multidrug-resistant Achromobacter in an 11-Year-old Boy With Cystic Fibrosis Assessed by Metagenome Analysis.

Pediatric Infectious Disease Journal 2023; 42: :754-759.

Choi J., Keen EC., Wallace MA., Fishbein S., Prusa J., Zimbric M., Mejia-Chew CR., Mehta SB., Bailey TC., Caverly LJ., Burnham CD., Dantas G.

Genomic Analyses of Longitudinal Mycobacterium abscessus Isolates in a Multicenter Cohort Reveal Parallel Signatures of In-Host Adaptation.

Journal of the Infectious Diseases 2023; 228: 321-331

Chandler CE, Hofstaedter CE, Hazen TH, Rasko DA, Ernst RK.

Genomic and Functional Characterization of Longitudinal Pseudomonas aeruginosa Isolates from Young Patients with Cystic Fibrosis.

Microbiology Spectrum. 2023; 11: e0155623.

Chung J, Eisha S, Park S, Morris AJ, Martin I
How Three Self-Secreted Biofilm

Exopolysaccharides of Pseudomonas aeruginosa, Psl, Pel, and Alginate, Can Each Be Exploited for Antibiotic Adjuvant Effects in Cystic Fibrosis Lung Infection.

International Journal of Molecular Sciences 2023; 24: e8709

de Souza Furtado J., de Almeida Brasiel PG., Luquetti SCPD.

Profile of the intestinal microbiota of patients with cystic fibrosis: A systematic review.

Clinical Nutrition ESPEN. 2023; 55: 400-406

Espinosa-Del-Barrio L., Boira I., Esteban V., Chiner E.

Mycobacterium malmoense Infection in a Patient With Adult Cystic Fibrosis: A Case Report.

Archivos de Bronconeumologia. 2023; 59: 540-541

Hirsch MJ., Hughes EM., Easter MM., Bollenbecker SE., Howze Iv PH., Birket SE., Barnes JW., Kiedrowski MR., Krick S.

A novel in vitro model to study prolonged Pseudomonas aeruginosa infection in the cystic fibrosis bronchial epithelium.

PLOS One 2023; 18: e0288002

Iwaniska A. Trafny EA., Czopowicz M., Augustynowicz-Kopee E.

Phenotypic and genotypic characteristics of Pseudomonas aeruginosa isolated from cystic fibrosis patients with chronic infections.

Scientific Reports 2023; 13: e11741

Jabalamel F., Emameini M., Beigverdi R., Halimi S., Siroosi M.

Determining effects of nitrate, arginine, and ferrous on antibiotic recalcitrance of clinical strains of *Pseudomonas aeruginosa* in biofilm-inspired alginate encapsulates.

Annals of Clinical Microbiology and Antimicrobials 2023; 22: e61

Hergenroeder GE., Faino AV., Cogen JD., Genatossio A., McNamara S., Pascual M., Hernandez RE.

Seroprevalence and clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis.

Pediatric Pulmonology. 2023; 58: 2478-2486

Kristensen M., de Koff EM., Chu ML., Groendijk S., Tramper-Stranders GA., de Winter-de Groot KM., Janssens HM., Tiddens HA., van Westreenen M., Sanders EAM., Arets BHGM., van der Ent CK., Prevaes SMPJ., Bogaert D.

16S rRNA-Based Microbiota Profiling Assists Conventional Culture Analysis of Airway Samples from Pediatric Cystic Fibrosis Patients
Microbiology Spectrum 2023; 11: e0405722

Kurbessoian T, Murante D, Crocker A, Hogan DA, Stajich JE.

In host evolution of *Exophiala dermatitidis* in cystic fibrosis lung micro-environment.
G3 (Bethesda) 2023; 13: jkad126

Llanos A., Achard P., Bousquet J., Lozano C., Zalacain M., Sable C., Revillet H., Murris M., Mittaine M., Lemonnier M., Everett M.

Higher levels of *Pseudomonas aeruginosa* LasB elastase expression are associated with early-stage infection in cystic fibrosis patients.
Scientific Reports 2023; 13: 14208

Leon-Icaza SA., Bagayoko S., Vergé R., Iakobachvili N., Ferrand C., Aydogan T., Bernard C., Sanchez Dafun A., Murris-Espin M., Mazières J., Bordignon PJ., Mazères S., Bernes-Lasserre P., Ramé V., Lagarde JM., Marcoux J., et al

Druggable redox pathways against *Mycobacterium abscessus* in cystic fibrosis patient-derived airway organoids.
PLOS Pathogens. 2023; 19: e1011559.

Li F., Hou CD., Lokareddy RK., Yang R., Forti F., Briani F., Cingolani G.

High-resolution cryo-EM structure of the *Pseudomonas bacteriophage* E217.
Nature Communications. 2023; 14: e4052

Liao YC., Huang YT., Tseng CH., Liu CW., Liu PY.

Comparative Genomics Identified PenR E151V Substitution Associated with Carbapenem-Resistance *Burkholderia cepacia* Complex and a Novel *Burkholderia cepacia* Complex Specific OXA-1043 Subgroup.

Infection and Drug Resistance 2023; 16: 5627-5635.

Komiya K, Yoshida M, Uchida S, Takikawa S, Yamasue M, Matsumoto T, Morishige Y, Aono A, Hiramatsu K, Yamaoka Y, Nishizono A, Ato M, Kadota JI, Mitarai S.

Massive and Lengthy Clonal Nosocomial Expansion of *Mycobacterium abscessus* subsp. *massiliense* among Patients Who Are Ventilator Dependent without Cystic Fibrosis.

Microbiology Spectrum 2023; 11: :e0490822

Kurbessoian T, Murante D, Crocker A, Hogan DA, Stajich JE.

In host evolution of *Exophiala dermatitidis* in cystic fibrosis lung micro-environment.
G3 (Bethesda) 2023; 13: jkad126

Marshall JE., Mercaldo RA., Lipner EM., Prevots DR.

Incidence of nontuberculous mycobacteria infections among persons with cystic fibrosis in the United States (2010-2019).
BMC Infectious Diseases 2023; 23: e489

Millar BC., McCaughan J., Rendall JC., Moore JE.

Infection dynamics of *Stenotrophomonas maltophilia* in patients with cystic fibrosis.
Journal of Infection. 2023; 86: 626-628

Mirhakkak MH., Chen X., Ni Y., Heinekamp T., Sae-Ong T., Xu LL., Kurzai O., Barber AE., Brakhage AA., Boutin S., Schäuble S., Panagiotou G.

Genome-scale metabolic modeling of *Aspergillus fumigatus* strains reveals growth dependencies on the lung microbiome.
Nature Communications. 2023; 14: 4369.

Murante D., Demers EG., Kurbessoian T., Ruzic M., Ashare A., Stajich JE., Hogan DA.
MRS4 loss of function in fungi during adaptation to the cystic fibrosis lung.
mBio 2023; 14: e0117123.

O'Dea AL., Feng R., Glaser LJ., Kubrak C., Rubenstein RC., Dorgan DJ., Hadjiliadis D., Kawut SM., Hong G..

The Clinical Association between *Aspergillus fumigatus* and Respiratory Outcomes in Adolescents and Adults with Cystic Fibrosis.
Annals of the American Thoracic Society. 2023; 20: :984-992

Olsen NS., Nielsen TK., Cui L., Dedon P., Neve H., Hansen LH., Kot W.

A novel Queuovirinae lineage of *Pseudomonas aeruginosa* phages encode dPreQ0 DNA modifications with a single GA motif that provide restriction and CRISPR Cas9 protection in vitro. *Nucleic Acids Research*. 2023; 51: 8663-8676

Olsen NS., Nielsen TK., Cui L., Dedon P., Neve H., Hansen LH., Kot W.

A novel Queuovirinae lineage of *Pseudomonas aeruginosa* phages encode dPreQ0 DNA modifications with a single GA motif that provide restriction and CRISPR Cas9 protection in vitro *Nucleic Acids Research* 2023; 28: gkad622

Palaniappan M., Ayub II., Joseph S., Vetrivel A., Ramasamy J., Natchimuthu S., Senthil K., Ramasamy M., Murugesan R.

Combined machine learning and pharmacophore based virtual screening approaches to screen for antibiofilm inhibitors targeting LasR of *Pseudomonas aeruginosa*.

Journal of Biomolecular Structure and Dynamics 2023; 41: 4124-4142

Palla J., Thapa S., Venkatachalam A., Runge JK., Laguna TA., Luna RA.

The upper airway microbiome in Hispanic children with cystic fibrosis.

Pediatric Pulmonology. 2023; 58: 2298-2307

Parfitt KM., Green AE., Connor TR., Neill DR., Mahenthiralingam E.

Identification of two distinct phylogenomic lineages and model strains for the understudied cystic fibrosis lung pathogen *Burkholderia multivorans*.

Microbiology 2023; 8: 1099/mic.0.001

Parmar S., Tocheva EI.

he cell envelope of *Mycobacterium abscessus* and its role in pathogenesis

PLoS Pathogens 2023; 19: e1011318.

Pita T., Feliciano JR., Leitão JH..

Identification of *Burkholderia cenocepacia* non-coding RNAs expressed during *Caenorhabditis elegans* infection.

Applied Microbiology and Biotechnology 2023; 107: 3653-3671.

Prem Suriya J., Mosbahi K., Atanaskovic I., Kleanthous C., Walker D.

Outer membrane translocation of pyocins via the copper regulated TonB-dependent transporter CrtA.

Biochemical Journal 2023; 480: 1035-1049.

Price CE., Hampton TH., Valls RA., Barrack KE., O'Toole GA., Madan JC., Coker MO.

Development of the intestinal microbiome in cystic fibrosis in early life.

mSphere 2023; 8: e0004623.

Ryan H., Ballard E., Stockwell RE., Duplancic C., Thomson RM., Smith K., Bell SC

A systematic review of the clinical impact of small colony variants in patients with cystic fibrosis.

BMC Pulmonary Medicine 2023; 23: e323

Sahl C., Baumgarten M., Shannon O., Pählman LI.

Exoproducts of the Most Common *Achromobacter* Species in Cystic Fibrosis Evoke Similar Inflammatory Responses In Vitro.

Microbiology Spectrum 2023; 11: e0019523

Sanchez H, O'Toole GA, Berwin B.

Assessment of the Glycan-Binding Profile of *Pseudomonas aeruginosa* PAO1

Microbiology Spectrum. 2023; 11: e0166723

Scott AJ., Ellis SR., Hofstaedter CE., Heeren RMA., Ernst RK.

Spatial lipidomics reveals biased phospholipid remodeling in acute *Pseudomonas* lung infection. *iScience* 2023; 26: 107700.

Sur S., Patra T., Karmakar M., Banerjee A.

Mycobacterium abscessus: insights from a bioinformatic perspective.

Critical Reviews in Microbiology 2023; 49: 499-514

Thangaswamy D.

Allergic bronchopulmonary aspergillosis presenting as complete lung collapse with respiratory failure.

BMJ Case Reports 2023; 16: :e252828

he cell envelope of *Mycobacterium abscessus* and its role in pathogenesis

Nutrition

Bergagnini-Kolev MC., Hsu S., Aitken ML., Goss CH., Hoofnagle AN., Zelnick LR., Lum D., Best CM., Thummel KE., Kestenbaum BR., de Boer IH., Lin YS.

Metabolism and pharmacokinetics of vitamin D in patients with cystic fibrosis.

Journal of Steroid Biochemistry and Molecular Biology. 2023; 232: e106332.

Sohouli MH., Magalhães EIDS., Ghahramani S., Nasresfahani M., Ezoddin N., Sharifi P., Rohani P.

Impact of omega-3 supplementation on children and adolescents patients with cystic fibrosis: A systematic review and meta-analysis of randomized-controlled trials.

Pediatric Pulmonology 2023; 58: 2219-2228

Wu M., Bhimavarapu A., Alvarez JA., Hunt WR., Tangpricha V..

Changes in bone turnover after high-dose vitamin D supplementation during acute pulmonary exacerbation in cystic fibrosis.

Bone 2023; 174: 116835.

Oral Aspects

Chin D., Ramalingam L., Harrison J., Silva M.

Oral health and cystic fibrosis in pediatrics: A survey of health professionals.

Pediatric Pulmonology 2023; 58: 1746-1752

Physiotherapy

Benz C., Middleton A., Elliott A., Harvey A.

Physiotherapy via telehealth for acute respiratory exacerbations in paediatric cystic fibrosis.

Journal of Telemedicine and Telecare 2023; 29: 552-560

Psychosocial

Desai S., Zhang W., Sutherland JM., Singer J., Quon BS.

Factors associated with frequent high-cost individuals with cystic fibrosis and their healthcare utilization and cost patterns.

Scientific Reports 2023; 13: e8910.

Glasscoe C., Hope HF., Lancaster GA., McCray G., West K., Patel L., Patel T., Hill J(7), Quittner AL., Southern KW.

Development and preliminary validation of the challenges of living with cystic fibrosis (CLCF) questionnaire: a 46-item measure of treatment burden for parent/carers of children with CF.

Psychology & Health 2023; 38: 1309-1344

Hager A., Wannheden C.

N-of-1 Analytics Makerspace: A Prototype for Cystic Fibrosis Self-Care and Co-Care.

Studies in Health Technology and Informatics. 2023; 302: 480-481.

Hamberger ES., Halpern-Felsher B.

Concern over tobacco and marijuana perceptions and use among adolescents and young adults with cystic fibrosis.

Addictive Behaviors 2023; 142: e:107669

Keogh RH., Gran JM., Seaman SR., Davies G., Vansteelandt S.

Causal inference in survival analysis using longitudinal observational data: Sequential trials and marginal structural models.

Statistics in Medicine 2023; 42: :2191-2225

Kimball H., Cobham VE., Sanders M., Douglas T.

Procedural anxiety among children and adolescents with cystic fibrosis and their parents.

Pediatric Pulmonology 2023; 58: 1967-1976

Niehammer U., Straßburg S., Sutharsan S., Taube C., Welsner M., Stehling F., Hirtz R.

How personality influences health outcomes and quality of life in adult patients with cystic fibrosis.

BMC Pulmonary Medicine 2023; 23: e190

Noij L., Haarman E., Hashimoto S., Terheggen-Lagro S., Altenburg J., Twisk J., Verkleij M.

Depression, anxiety, and resilience during COVID-19 in Dutch patients with cystic fibrosis or primary ciliary dyskinesia and their caregivers.

Pediatric Pulmonology. 2023; 58: 2025-2034.

Muilwijk D., van Paridon TJ., van der Heijden DC., Faber-Bisschop BM., Zomer-van Ommen DD., Heijerman HGM., van der Ent CK.

Development and validation of a novel personalized electronic patient-reported outcome measure to assess quality of life (Q-LIFE): a prospective observational study in people with Cystic Fibrosis.

eClinicalMedicine 2023; 62: e102116

Ortiz Ortigosa L., Vinolo-Gil MJ., Pastora Bernal JM., Casuso-Holgado MJ., Rodriguez-Huguet M., Martín-Valero R.

Telerehabilitation and telemonitoring interventions programs used to improving quality of life in people with cystic fibrosis: A systematic review.

Digital Healthcare 2023; 9: 20552076231197

Perkins RC., Sawicki GS.

High deductible insurance plans impart economic burden for people with cystic fibrosis.

Pediatric Pulmonology 2023; 58: 1798-1801

Quittner AL., Barker D., Graziano S., Georgiopoulos AM., Muther E., Verkleij M., Schechter MS., Tillman L., Mueller A., Lomas P., Hempstead S., Smith BA.

National integration of mental health screening and treatment into specialized care for cystic fibrosis: What predicts success?

Pediatric Pulmonology 2023; 58: 1768-1776

South K., Smaldone A., Sadeghi H., Piane V., Kowal R., Wei L., George M.

Parent and adolescent perceptions of cystic fibrosis management responsibility: A mixed-methods study.

Pediatric Pulmonology 2023; 58: 2340-2351

van der Heijden E., van den Bor RM., van der Ent CK., Nijhof SL., van der Laan SEI.

The RISE study protocol: resilience impacted by positive stressful events for people with cystic fibrosis.

ERJ Open Research 2023; 9: 00535-2022.

Woolley JC., Edmondson SN., Sathe MN., Rodriguez Francis JK.

Patient Attitudes Regarding Health Care Clinician Communication in Adolescents With Cystic Fibrosis.

Journal of Pediatric Gastroenterology and Nutrition. 2023; 77: e23-e28

Verkleij M., Georgiopoulos AM., Barendrecht H., Friedman D.

Pilot of a therapist-guided digital mental health intervention (eHealth CF-CBT) for adults with cystic fibrosis.

Pediatric Pulmonology 2023; 58: :2094-2103

Pulmonology

Alam FS., Zanette B., Munidasa S., Braganza S., Li D., Woods JC., Ratjen F., Santyr G.

Intra- and Inter-visit Repeatability of (129) Xenon Multiple-Breath Washout MRI in Children With Stable Cystic Fibrosis Lung Disease.

Journal of Magnetic Resonance Imaging 2023; 58: :936-948

Athanazio RA., Tanni SE., Ferreira J., Dalcin PTR., Fuccio MB., Esposito C., Canan MGM., Coelho LS., Firmida MC., Almeida MB., Marostica PJC., Monte LFV., Souza EL., Pinto LA., Rached SZ., Oliveira VSB., Riedi CA., Silva Filho..

Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association).

Jornal Brasileiro de Pneumologia 2023; 49: e20230040

Caparrós-Martín JA., Saladie M., Agudelo-Romero SP., Reen FJ., Ware RS., Sly PD., Stick SM., O'Gara F.; COMBAT study group.

Detection of bile acids in bronchoalveolar lavage fluid defines the inflammatory and microbial landscape of the lower airways in infants with cystic fibrosis.

Microbiome. 2023; 11: e132

Cascio F., Gazia F., D'Alcontres FS., Felippu AWD., Migliorato A., Rizzo G., Palmeri S., Felippu AWD., Lucanto MC., Costa S., Cascio F.

The centripetal endoscopic sinus surgery in patients with cystic fibrosis: A preliminary study. *American Journal of Otolaryngology* 2023; 44: e103912.

Depiazzi J., Bourke C., Stick S., Withers A.

Prevalence of tracheobronchomalacia is higher than previously reported in children with cystic fibrosis.

Pediatric Pulmonology 2023; 58: 2568-2573

Douglas LEJ., Reihill JA., Montgomery BM., Martin SL.

Furin as a therapeutic target in cystic fibrosis airways disease.

European Respiratory Review. 2023; 32: e:220256

Essilfie AT., Houston N., Maniam P., Hartel G., Okano S., Reid DW.

Anti-protease levels in cystic fibrosis are associated with lung function, recovery from pulmonary exacerbations and may be gender-related.

Respirology. 2023; 28: :533-542

Goetz DM., Frederick CK., Perez G., Borowitz D.

Airway clearance after highly effective CFTR modulators: Normalizing life and reducing treatment burden.

Pediatric Pulmonology 2023; 58: :2375-2380

Jones M., Moffatt F., Harvey A., Ryan JM.

Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis.

Cochrane Database of Systematic Reviews 2023; 7: CD013610

Love AJ., Quon BS.

Falling through the Cracks-The Impact of Care Gaps on Lung Function Loss in Cystic Fibrosis. *Annals of the American Thoracic Society* 2023; 20: 1235-1236.

Masson VK., Nussbaum E., Gelb AF., Tashkin DP., Randhawa I., Nadel JA, Fireizen Y., De Celie-Germana JK., Madera D., Senanayake D.

Isolated abnormal FEF75% detects unsuspected bronchiolar obstruction in CF children.

Pediatric Research 2023; 94: 1051-1056

McCafferty K., Henderson J., Mulrennan S., Jamieson J., Properzi C., Tai A.

Measuring energy requirements during pulmonary exacerbations of cystic fibrosis using indirect calorimetry.

Nutrition 2023; 112: e112073

Oates GR., Schechter MS.

Aiming to Improve Equity in Pulmonary Health: Cystic Fibrosis.

Clinics in Chest Medicine 2023; 44: 555-573

Sears EH Jr., Hinton AC., Lopez-Pintado S., Lary CW., Zuckerman JB.

Gaps in Cystic Fibrosis Care Are Associated with Reduced Lung Function in the U.S. Cystic Fibrosis Foundation Patient Registry.

Annals of the American Thoracic Society 2023; 20: 1250-1257

Szczesniak R., Andrinopoulou ER., Su W., Afonso PM., Burgel PR., Cromwell E., Gecili E., Ghulam E., Goss CH., Mayer-Hamblett N., Keogh RH., Liou TG., Marshall B., Morgan WJ., Ostrenga JS., Pasta DJ., Stanojevic S., Wainwright C., Zhou GC., et al

Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations.

Annals of the American Thoracic Society 2023; 20: 958-968

Terlizzi V., Fevola C., Ferrari B., Castellani C., Santini G., Innocenti D., Masi E., Bonomi P., Lombardi E., Taccetti G.

Lung clearance index in children with cystic fibrosis previously diagnosed with CRMS/CFSPID: A monocentric prospective experience.

Pediatric Pulmonology. 2023; 58: 2124-2131

Vyas AP., Ananthaneni A., Abdehou S., Pandit S.

Esophageal squamous cell carcinoma at the site of tracheo-esophageal fistula repair in a patient with cystic fibrosis.

BMJ Case Reports 2023; 16: e253542.

Wainwright CE.

Airway inflammation and lung function in cystic fibrosis.

Respirology 2023; 28: :509-510

Radiology

Alexandre-Heymann L., Puerto M., Martin C., Burnet E., Mosnier-Pudar H., Burgel PR., Larger E.

CT imaging shows specific pancreatic abnormalities in persons with cystic fibrosis related diabetes.

Scientific Reports 2023; 13: e10433.

Bayfield KJ., Weinheimer O., Boyton C., Fitzpatrick R., Middleton A., Kennedy B., Blaxland A., Jayasuriya G., Caplain N., Issa H., Goetti R., Wielpütz MO., Yu L., Galban CJ., Robinson TE., Bartholmai B., Fitzgerald D., Selvadurai H., Robinson PD.

Implementation and evaluation of ultra-low dose CT in early cystic fibrosis lung disease.

European Respiratory Journal. 2023; 62: e2300286

Biederer J.

MR imaging of the airways.

British Journal of Radiology 2023; 96: e20220630

Chung SH., Huynh KM., Goralski JL., Chen Y., Yap PT., Ceppe AS., Powell MZ., Donaldson SH., Lee YZ.

Feasibility of free-breathing (19) F MRI image acquisition to characterize ventilation defects in CF and healthy volunteers at wash-in.

Magnetic Resonance in Medicine 2023; 90: :79-89

Eischen E., Gliksman MF., Segarra D., Murtagh RD., Ryan LE., Parasher AK., Tabor MH.

Correlation between CT imaging and symptom scores in cystic fibrosis associated chronic sinusitis

American Journal of Otolaryngology 2023; 44: e103858

Kern AL.

Editorial for "Intra- and Inter-visit Repeatability of (129) Xenon Multiple-Breath Washout MRI in Children With Stable Cystic Fibrosis Lung Disease".

Journal of Magnetic Resonance Imaging 2023; 58: 949-950

Marshall H., Voskrebenezv A., Smith LJ., Biancardi AM., Kern AL., Collier GJ., Wielopolski PA., Ciet P., Tiddens HAWM., Vogel-Claussen J., Wild JM.

(129) Xe and Free-Breathing (1) H Ventilation MRI in Patients With Cystic Fibrosis: A Dual-Center Study.

Journal of Magnetic Resonance Imaging 2023; 57: 1908-1921

Screening

Bedran RM., Alvim CG., Sader OG., Alves Júnior JV., Pereira FH., Nolasco DM., Zhang L., Camargos P.

Sweat conductivity for diagnosing cystic fibrosis after positive newborn screening: prospective, diagnostic test accuracy study.

Archives of Disease in Childhood. 2023; 108: :538-542

Escudero-Ávila R., Delgado-Pecellín C., Moreno-Valera MJ., Carrasco-Hernández L., Quintana-Gallego ME., Delgado-Pecellín I.

False negatives in the newborn screening for cystic fibrosis in Western Andalusia: Results from a 10-year experience.

Pediatric Pulmonology 2023; 58: 2464-2468.

Therapy

No authors listed

Simplifying CFTR modulation therapy in cystic fibrosis.

Archives of Disease in Childhood 2023; 108: 615

Aalbers BL., Mohamed Hoesein FAA., Hofland RW., Bronsveld I., Kruijswijk MA., Schotman S., Slingerland CW., Panhuis H., van der Ent CK, Heijerman HGM.

Radiological and long-term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease.

Pediatric Pulmonology 2023; 58: 2317-2322

Addante A., Raymond W., Gitlin I., Charbit A., Orain X., Scheffler AW., Kuppe A., Duerr J., Danilchenko M., Drescher M., Graeber SY., Healy AM., Oscarson S., Fahy JV., Mall MA.

A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases

European Respiratory Journal 2023; 61: e2202022

Bathgate CJ., Muther E., Georgiopoulos AM., Smith B., Tillman L., Graziano S., Verkleij M., Lomas P., Quittner A. Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers' observations across US centers. *Pediatric Pulmonology* 2023; 58: 2469-2477

Bergagnini-Kolev M., Kane K., Templeton IE., Curran AK.

Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data.

AAPS Journal 2023; 25: e62

Birimberg-Schwartz L., Ip W., Bartlett C., Avolio J., Vonk AM., Gunawardena T., Du K., Esmaeili M., Beekman JM., Rommens J., Strug L., Bear CE., Moraes TJ., Gonska T. Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis.

Life Science Alliance 2023; 6: e20220

Bode SFN., Rapp H., Lienert N., Appel H., Fabricius D.

Effects of CFTR-modulator triple therapy on sinusal symptoms in children and adults with cystic fibrosis.

European Archives of Oto-Rhino-Laryngology 2023; 280: 3271-3277

Brusa I., Sondo E., Pesce E., Tomati V., Gioia D., Falchi F., Balboni B., Ortega Martínez JA., Veronesi M., Romeo E., Margaroli N., Recanatini M., Girotto S., Pedemonte N., Roberti M., Cavalli A.

Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5. *Journal of Medicinal Chemistry.* 2023; 66: 9797-9822

Chu C., Lu M., Menon P., Waltz D., Weinstock T., Zelazoski L., Davies JC.

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.

American Journal of Respiratory and Critical Care Medicine 2023; 208: 68-78

Donaldson SH.

More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice.

European Respiratory Journal. 2023; 62: e2300865

Dwyer TJ., Elkins MR., Dentice R., Forbes S., Cooper P., Jaffe A., Bishop J., Middleton PG., Wark P., Bye PTP.; SALT I-CF Study Group. Saline at lower tonicity in cystic fibrosis (SALT I-CF) trial comparing 0.9% versus 3% versus 6% nebulised saline.

European Respiratory Journal 2023; 62: e2100960

Fainardi V., Skenderaj K., Ciuni A., Esposito S., Sverzellati N., Pisi G.

Effect of elexacaftor-tezacaftor-ivacaftor modulator on lung structure in cystic fibrosis

Pulmonology. 2023; 29: 441-443

Fainardi V., Skenderaj K., Ciuni A., Milanese G., Deolmi M., Longo F., Spaggiari C., Sverzellati N., Esposito S., Pisi G.

Structural changes in lung morphology detected by MRI after modulating therapy with elexacaftor/tezacaftor/ivacaftor in adolescent and adult patients with cystic fibrosis.

Respiratory Medicine 2023; 16: 107328.

Gramegna A., Majo F., Alicandro G., Leonardi G., Cristiani L., Amati F., Contarini M., Aliberti S., Fiocchi AG., Blasi F.

Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis.

Respiratory Research 2023; 24: e164

Granados A., Chan CL., Moheet A., Vigers T., Arbeláez AM., Larson Ode K.

The impact of elexacaftor/tezacaftor/ivacaftor on body composition in a small cohort of youth with cystic fibrosis.

Pediatric Pulmonology. 2023; 58: 1805-1811

Gushue C., Eisner M., Bai S., Johnson T., Holtzlander M., McCoy K., Sheikh S.

Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis

Pediatric Pulmonology. 2023; 58: :2308-2316

Han X, Li D, Reyes-Ortega F, Schneider-Futschik EK.

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis.

Pharmaceutics 2023; 15: e1488

Jiménez-Gómez M., Díaz Campos RM., Diab Cáceres L.

Cystic Fibrosis-Asthma Overlap Syndrome. Combination of Cystic Fibrosis Transmembrane Conductance Regulator Modulators and Type 2 Targeted Biologic Treatment for Asthma.

Archivos de Bronconeumologia 2023; 59: 512-513

Mehta AM., Lee I., Li G., Jones MK., Hanson L., Lonabaugh K., List R., Borish L., Albon DP.

The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis.

Allergy, Asthma & Clinical Immunology 2023; 19: e66

Monogue ML., Sanders JM., Pybus CA., Kim J., Zhan X., Clark AE., Greenberg DE.

Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related *Pseudomonas aeruginosa* infections.

JAC-Antimicrobial Resistance 2023; 5: dlad083

McNally P., Linnane B., Williamson M., Elnazir B., Short C., Saunders C., Kirwan L., David R., Kemner-Van de Corput MPC., Tiddens HAWM., Davies JC., Cox DW.

The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6-11 with cystic fibrosis in a real-world setting. *Respiratory Research*. 2023; 24: e199

Nichols DP., Morgan SJ., Skalland M., Vo AT., Van Dalen JM., Singh SB., Ni W., Hoffman LR., McGeer K., Heltshe SL., Clancy JP., Rowe SM., Jorth P., Singh PK.; PROMISE-Micro Study Group.

Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.

Journal of Clinical Investigation. 2023; 133: e167957

Perrem L., Ratjen F.

A new triple combination cystic fibrosis transmembrane regulator modulator.

Lancet Respiratory Medicine 2023; 11: 499-500

Schaupp L Addante A, Völler M, Fentker K, Kuppe A, Bardua M, Duerr J, Piehler L, Röhm J., Thee S., Kirchner M., Ziehm M., Lauster D., Haag R., Gradzielski M., Stahl M., Mertins P, Boutin S, Graeber SY, Mall MA.

Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. *European Respiratory Journal*. 2023; 62: e2202153

Solís García M, Madrid Carbajal C., Girón Moreno RM.

Acute cholecystitis in cystic fibrosis patients after initiation of treatment with elexacaftor/tezacaftor/ivacaftor. [Article in English, Spanish]

Medicina Clínica 2023; 160: e5-e6.

Southern KW., Barben J., Goldring S., Kneen R., Southward S., Rajeev Y., Davies JC., Bush A.

Raised Intracranial Pressure in Three Children with Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor Modulator Therapy.

American Journal of Respiratory and Critical Care Medicine 2023; 208: :103-105

Stahl M., Roehmel J., Eichinger M., Doellinger F., Naehrlich L., Kopp MV., Dittrich AM., Lee C., Sommerburg O., Tian S., Xu T. Wu P., Joshi A., Ray P., Duncan ME., Wielpütz MO., Mall MA.

Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial.

Annals of the American Thoracic Society 2023; 20: 1144-1155

Sutharsan S., Dillenhoefer S., Welsner M., Stehling F., Brinkmann F., Burkhardt M., Ellemunter H., Dittrich AM., Smaczny C., Eickmeier O., Kappler M., Schwarz C., Sieber S., Naehrig S., Naehrlich L.; German CF Registry

Impact of ellexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry.

Lancet Regional Health - Europe 2023; 32: e100690

Tunney MM., Wark P.

Long-term therapy with ellexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist.

European Respiratory Journal 2023; 62: e2301008

Uluer AZ., MacGregor G., Azevedo P., Indihar V., Keating C., Mall MA., McKone EF., Ramsey BW., Rowe SM., Rubenstein RC., Taylor-Cousar JL., Tullis E., Yonker LM., Chu C., Lam AP., Nair N., Sosnay PR., Tian S., Van Goor F., Viswanathan L., et al

Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.

Lancet Respiratory Medicine 2023; 11: 550-562

Uytun S., Cinel G., Eryilmaz Polat S., Özkan Tabakçi S., Kiper N., Yalçın E., Ademhan Tural D., Özsezen B., Sen V., Selimoglu Sen H., Ufuk Altintas D., Çokugras H., Kiliç AA., Baskan AK., Yazan H., Çollak A., Uzuner S., et al

Patients with cystic fibrosis who could not receive the CFTR modulator treatment: What did they lose in 1 year?

Pediatric Pulmonology 2023; 58: 2505-2512

Vanherle L., Matthes F., Uhl FE., Meissner A. Ivacaftor therapy post myocardial infarction augments systemic inflammation and evokes contrasting effects with respect to tissue inflammation in brain and lung.

Biomedicine & Pharmacotherapy. 2023; 162: e114628.

Vincken S., Verbanck S., Braun S., Buyck N., Knoop C., Vanderhelst E.

Real-world data on the efficacy and safety of tezacaftor-ivacaftor in adults living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation.

Acta Clinica Belgica 2023; 78: 280-284

Vu HD., Shafuddin E., Willis J., Pallin M., Armstrong D., Daley C.

Monoclonal antibody therapy in cystic fibrosis and asthma.

Respirology 2023; 28: 571-574

Wainwright C., McColley SA., McNally P., Powers M., Ratjen F., Rayment JH., Retsch-Bogart G., Roesch E., Ahluwalia N., Chin A., Wark P., McDonald VM., Smith S.

Nebulised hypertonic saline for cystic fibrosis.

Cochrane Database of Systematic Reviews: 2023; 6: CD001506

Transplantation

Fessler J., Glorion M., Finet M., Soniak C., de Verdiere SC., Sage E., Roux A., Zuber B., Fischler M., Guen ML., Vallée A.

Perioperative Outcomes During Double-Lung Transplantation and Retransplantation in Cystic Fibrosis Patients: A Monocentric Cohort Study . *Journal of Cardiothoracic and Vascular Anesthesia* 2023; 37: :964-971.

Gauvreau A., Carrier FM., Poirier C., Morisset J., Lands LC., Lavoie A., Nasir B., Ferraro P., Luong ML.

Post-transplant outcomes among cystic fibrosis patients undergoing lung transplantation colonized by Burkholderia: A single center cohort study. *Journal of Heart and Lung Transplantation* 2023; 42: 917-924.

Guzman-Gomez A., Ahmed HF., Dani A., Zafar F., Lehenbauer DG., Potter AS., Morales DLS., Ziady AG., Hayes D Jr.

Center volume effect on acute cellular rejection and outcomes in pediatric lung transplant recipients.

Journal of Heart and Lung Transplantation. 2023; 42: 1030-1039.

Jones J.

A cystic fibrosis patient.

Current Opinion in Organ Transplantation 2023;
28: 188-191

Ponte C., Alkhatiri O., Olland A., Falcoz PE.

Donors in lung transplantation: does age matter?

*Interdisciplinary CardioVascular and Thoracic
Surgery*, 2023; 37: ivad111